Search results for " prognostic"

showing 9 items of 139 documents

Efficacy, Safety, and Confirmation of the Recommended Phase 2 Starting Dose of the Combination of Ruxolitinib (RUX) and Panobinostat (PAN) in Patient…

2015

Abstract BACKGROUND: MF is a myeloproliferative neoplasm characterized by bone marrow (BM) fibrosis, splenomegaly, and debilitating constitutional symptoms. RUX is a potent JAK1/JAK2 inhibitor that has demonstrated superiority in spleen volume reduction, symptom improvement, and survival in the phase 3 COMFORT studies compared with placebo and best available therapy. PAN, a potent pan-deacetylase inhibitor, inhibits JAK signaling by disrupting the interaction between JAK2 and heat shock protein 90, a protein chaperone. PAN has demonstrated reductions in splenomegaly and improvement of BM fibrosis in phase 1/2 studies. The combination of RUX and PAN demonstrated synergistic activity in precl…

medicine.medical_specialtyRuxolitinibThrombocytosisCombination therapybusiness.industryImmunologyCell BiologyHematologymedicine.diseasePlaceboBiochemistrychemistry.chemical_compoundchemistryTolerabilityInternational Prognostic Scoring SystemPanobinostatInternal medicineImmunologymedicineMyelofibrosisbusinessmedicine.drugBlood
researchProduct

A Phase 1b, Dose-Finding Study Of Ruxolitinib Plus Panobinostat In Patients With Primary Myelofibrosis (PMF), Post–Polycythemia Vera MF (PPV-MF), Or …

2013

Abstract Background Myelofibrosis (MF) is a myeloproliferative neoplasm associated with progressive, debilitating symptoms that impact patient quality of life (QoL) and reduce survival. Ruxolitinib (RUX), a potent dual JAK1/JAK2 inhibitor, demonstrated superiority in spleen volume and symptom reduction, improved health-related QoL measures, and prolonged survival compared with traditional therapies or placebo in the phase 3 COMFORT studies. Panobinostat (PAN) is a potent oral pan-deacetylase inhibitor (DACi) that inhibits JAK pathway signaling through increased acetylation of the JAK2 protein chaperone HSP90. In phase 1/2 studies in MF, PAN has shown reduction in splenomegaly and JAK2 V617F…

medicine.medical_specialtyRuxolitinibbusiness.industryeducationImmunologyCell BiologyHematologymedicine.diseasePlaceboOff-label useBiochemistryDiscontinuationInternational Prognostic Scoring SystemInternal medicineCohortImmunologymedicineMyelofibrosisbusinessAdverse effecthealth care economics and organizationsmedicine.drugBlood
researchProduct

Ofatumumab (OFA) in Combination with CHOP for Previously Untreated Follicular Lymphoma: Follow-up Results

2012

Abstract Abstract 1632 Background: OFA is a fully human monoclonal antibody that binds to both the large and small extracellular loops of CD20. OFA is currently approved for patients (pts) with refractory chronic lymphocytic leukemia and has demonstrated activity in non-Hodgkin's lymphomas, including follicular lymphoma (FL). We previously reported results of a phase II study of OFA in combination with CHOP (cyclophosphamide 750 mg/m2, doxorubicin 50 mg/m2, vincristine 1.4 mg/m2, prednisone 100 mg daily for 5 days) chemotherapy (O-CHOP) in pts with previously untreated FL (Czuczman et al. Br J Haematol. 2012;157:438). We now report updated efficacy, safety and pharmacokinetic (PK) follow-up…

medicine.medical_specialtyVincristineImmunologyFollicular lymphomaPhases of clinical researchCHOPOfatumumabBiochemistryGastroenterology03 medical and health scienceschemistry.chemical_compound0302 clinical medicineInternational Prognostic IndexPrednisoneInternal medicinemedicinebusiness.industryCell BiologyHematologymedicine.diseaseChemotherapy regimen3. Good healthSurgerychemistry030220 oncology & carcinogenesisbusiness030215 immunologymedicine.drug
researchProduct

Calculated Whole Blood Viscosity and Albumin/Fibrinogen Ratio in Patients with a New Diagnosis of Multiple Myeloma: Relationships with Some Prognosti…

2023

Background: In this single center study, we retrospectively evaluated the calculated hemorheological profile in patients with a new diagnosis of multiple myeloma, with the aim to evaluate possible relationships with some prognostic predictors, such as ISS, albumin levels, beta2-microglobulin, red cell distribution width, and bone marrow plasma cell infiltration. Methods: In a cohort of 190 patients, we examined the calculated blood viscosity using the de Simone formula, and the albumin/fibrinogen ratio as a surrogate of erythrocyte aggregation, and then we related these parameters to prognostic factors, using the Kruskal–Wallis and the Mann–Whitney tests, respectively. Results: From our ana…

multiple myelomahemorheological patternmultiple myeloma; hemorheological pattern; calculated blood viscosity; albumin/fibrinogen ratio; prognostic factorsalbumin/fibrinogen ratioMedicine (miscellaneous)prognostic factors.calculated blood viscosityGeneral Biochemistry Genetics and Molecular BiologyBiomedicines; Volume 11; Issue 3; Pages: 964
researchProduct

ABSOLUTE LYMPHOCYTE COUNT IS NOT A PREDICTOR FOR SURVIVAL IN NEWLY DIAGNOSED ELDERLY PATIENTS WITH MULTIPLE MYELOMA. FINAL RESULTS OF A MULTICENTER S…

2012

multiple myeoloma lymphocite count prognostic factorsSettore MED/15 - Malattie Del Sangue
researchProduct

Cukrzyca typu 2 i przewlekła choroba nerek jako czynniki rokownicze w ostrym zapaleniu trzustki

2019

Przeprowadzono analizę czynników rokowniczych ostrego zapalenia trzustki (OZT). Dokonano krytycznego przeglądu najważniejszych skali rokowniczych OZT: Apache II, Ransona, BISAP, Sofa, Marshalla. Wskazano na ich ograniczenia, ale i przydatność kliniczną we wczesnej stratyfikacji prognostycznej OZT. W diagnostyce różnicowej należy wyodrębniać etiologię alkoholową i żółciopochodną. Występująca przed zachorowaniem cukrzyca typu 2 i przewlekła choroba nerek znamiennie pogarszają przebieg OZT i powinny być włączone do skali rokowniczych. Wykazano, że obecność cukrzycy z poziomem HBA1C powyżej 6,5% wiąże się ze zwiększoną śmiertelnością wśród chorych na OZT i wydłuża się okres hospitalizacji o 5 d…

przewlekła choroba nerekacute pancreatitisdiabetes type 2cukrzyca typu 2ostre zapalenie trzustkiznaczenie rokowniczeseverity and prognostic scaleskale ciężkości i rokowaniachronic kidney diseaseprognostic significancePostępy Higieny i Medycyny Doświadczalnej
researchProduct

Modified Glasgow Prognostic Score is Associated With Risk of Recurrence in Bladder Cancer Patients After Radical Cystectomy

2015

Recently, many studies explored the role of inflammation parameters in the prognosis of urinary cancers, but the results were not consistent. The modified Glasgow Prognostic Score (mGPS), a systemic inflammation marker, is a prognostic marker in various types of cancers. The aim of the present study was to investigate the usefulness of the preoperative mGPS as predictor of recurrence-free (RFS), overall (OS), and cancer-specific (CSS) survivals in a large cohort of urothelial bladder cancer (UBC) patients.A total of 1037 patients with UBC were included in this study with a median follow-up of 22 months (range 3-60 months). An mGPS = 0 was observed in 646 patients (62.3%), mGPS = 1 in 297 pa…

to-lymphocyte ratioAdultMaleRiskmedicine.medical_specialtyPrognosimedicine.medical_treatmentCystectomyGastroenterologySettore MED/24 - UrologiaCystectomyMedicine (all); c-reactive protein; advanced urothelial carcinoma; to-lymphocyte ratioc-reactive proteinRetrospective StudieInternal medicine80 and overHumansMedicineStage (cooking)advanced urothelial carcinomaRetrospective StudiesAgedAged 80 and overModified Glasgow Prognostic Score is Associated With Risk of Recurrence in Bladder Cancer Patients After Radical Cystectomy: A Multicenter Experience.Univariate analysisBladder cancerbusiness.industryProportional hazards modelMedicine (all)Hazard ratioBladder cancer Radical cystectomyRetrospective cohort studyGeneral MedicineMiddle AgedPrognosismedicine.diseaseSurgeryNeoplasm RecurrenceLocalUrinary Bladder NeoplasmsUrinary Bladder NeoplasmCohortFemaleNeoplasm Recurrence LocalAdult; Aged; Aged 80 and over; Female; Humans; Male; Middle Aged; Neoplasm Recurrence Local; Prognosis; Retrospective Studies; Risk; Urinary Bladder Neoplasms; Cystectomy; Medicine (all)businessHumanMedicine
researchProduct

Prognostic Factors in Staged Bilateral Total Knee Arthroplasty—A Retrospective Case Series Analysis

2023

Background: Bilateral osteoarthritis of the knee is an indication for a bilateral total knee replacement (TKR) procedure. The goal of our study was to assess the sizes of the implants used during the first and second stages of TKR procedures in order to compare their size and identify the prognostic factors for the second procedure. Methods: We evaluated 44 patients who underwent staged bilateral TKR procedures. We assess the following prognostic factors from the first and second surgery: duration of anesthesia, femoral component size, tibial component size, duration of hospital stay, tibial polyethylene insert size, and the number of complications. Results: All assessed prognostic factors …

total knee replacement; two-stage; prognostic factors; bilateral; predictive factorsGeneral MedicineJournal of Clinical Medicine; Volume 12; Issue 10; Pages: 3547
researchProduct

The evaluation of tumor budding in oral tongue squamous cell carcinoma patients: a novel prognostic histopathological grading system

2020

tumor budding oral tongue squamous cell carcinoma novel prognostic histopathological grading system
researchProduct